Literature DB >> 9433351

Validity of substance use self-reports in dually diagnosed outpatients.

R D Weiss1, L M Najavits, S F Greenfield, J A Soto, S R Shaw, D Wyner.   

Abstract

OBJECTIVE: The purpose of this study was to assess the validity of self-reports of substance use among outpatients dually diagnosed with substance use disorder and either bipolar disorder or posttraumatic stress disorder.
METHOD: Self-reports of substance use were compared with supervised urine samples collected on the same day for 55 subjects.
RESULTS: Self-reports were highly valid. Only 4.7% of cases involved subjects not reporting substance use detected by urine screens.
CONCLUSIONS: Self-reports of substance use may be highly valid in nonpsychotic, dually diagnosed outpatients under certain conditions, i.e., when patients are in treatment, when urine samples are collected with patients' prior knowledge, when patients are well-known to staff, and when honest self-reporting is encouraged.

Entities:  

Mesh:

Year:  1998        PMID: 9433351     DOI: 10.1176/ajp.155.1.127

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  28 in total

1.  Support, mutual aid and recovery from dual diagnosis.

Authors:  A B Laudet; S Magura; H S Vogel; E Knight
Journal:  Community Ment Health J       Date:  2000-10

2.  Treatment outcomes for veterans with PTSD and substance use: Impact of specific substances and achievement of abstinence.

Authors:  Ajay Manhapra; Elina Stefanovics; Robert Rosenheck
Journal:  Drug Alcohol Depend       Date:  2015-09-25       Impact factor: 4.492

3.  Seeking safety therapy for adolescent girls with PTSD and substance use disorder: a randomized controlled trial.

Authors:  Lisa M Najavits; Robert J Gallop; Roger D Weiss
Journal:  J Behav Health Serv Res       Date:  2006-10       Impact factor: 1.505

4.  Overview and initial validation of two detailed, multidimensional, retrospective measures of substance use: the Lifetime Substance Use Recall (LSUR) and Longitudinal Substance Use Recall for 12 Weeks (LSUR-12) Instruments.

Authors:  Claire E Ramsay; Glen R Abedi; John D Marson; Michael T Compton
Journal:  J Psychiatr Res       Date:  2010-05-20       Impact factor: 4.791

5.  An effectiveness trial of group cognitive behavioral therapy for patients with persistent depressive symptoms in substance abuse treatment.

Authors:  Katherine E Watkins; Sarah B Hunter; Kimberly A Hepner; Susan M Paddock; Erin de la Cruz; Annie J Zhou; Jim Gilmore
Journal:  Arch Gen Psychiatry       Date:  2011-06

6.  The cost-effectiveness of depression treatment for co-occurring disorders: a clinical trial.

Authors:  Katherine E Watkins; Alison E Cuellar; Kimberly A Hepner; Sarah B Hunter; Susan M Paddock; Brett A Ewing; Erin de la Cruz
Journal:  J Subst Abuse Treat       Date:  2013-10-02

7.  Factors affecting agreement between severely mentally ill alcohol abusers' and collaterals' reports of alcohol and other substance abuse.

Authors:  Paul R Stasiewicz; Paula C Vincent; Clara M Bradizza; Gerard J Connors; Stephen A Maisto; Nicole D Mercer
Journal:  Psychol Addict Behav       Date:  2008-03

8.  Gender differences in reactive and proactive aggression.

Authors:  Daniel F Connor; Ronald J Steingard; Jennifer J Anderson; Richard H Melloni
Journal:  Child Psychiatry Hum Dev       Date:  2003

9.  A "community-friendly" version of integrated group therapy for patients with bipolar disorder and substance dependence: a randomized controlled trial.

Authors:  Roger D Weiss; Margaret L Griffin; William B Jaffee; Rachel E Bender; Fiona S Graff; Robert J Gallop; Garrett M Fitzmaurice
Journal:  Drug Alcohol Depend       Date:  2009-07-01       Impact factor: 4.492

10.  HIV risk behavior among patients with co-occurring bipolar and substance use disorders: associations with mania and drug abuse.

Authors:  Christina S Meade; Fiona S Graff; Margaret L Griffin; Roger D Weiss
Journal:  Drug Alcohol Depend       Date:  2007-09-11       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.